Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 5Active not recruiting 5Unknown 2Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 19Thoracic 6Lymphoid 3Tumor-Agnostic 2Sarcoma 2

Conditions

Rhabdomyosarcoma 2

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Surgical Procedures, Operative 14Magnetic Resonance Spectroscopy 14Gemcitabine 13Blood Specimen Collection 13Biopsy 13Radiotherapy 12fludarabine 11atezolizumab 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 6selinexor 5liposomal doxorubicin 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Vinorelbine × Sarcoma × Clear all
NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

St. Jude Children's Research Hospital

Phase 2 Recruiting
135 enrolled
Sarcoma

Rhabdomyosarcoma

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting
1,672 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡